Clinical Trial

Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens

Study acronym: VAMPAIR
Recruiting
View on ClinicalTrials.gov →
Summary
Ventilator-associated pneumonia (VAP) remains one of the main nosocomial infections acquired in the intensive care unit (ICU). VAP is pneumonia occurring 48 hours after intubation. Today, bronchoalveolar lavage (BAL) is used for microbiological diagnosis, with bacterial culture and antibiotic susceptibility results within 48 to 72 hours. Multiplex PCR can detect DNA of a number of bacteriae, as well as the presence of resistance genes. However, its clinical value in the ICU remains to be demonstrated. We think that the use of multiplex PCR with a panel adapted to the microbiology of VAP, could be an interesting method for clinicians in ICU.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-12.
Status change: Not Yet Recruiting → Recruiting 2025-06-13
Trial Details
NCT Number NCT06554327
Lead Sponsor CHU de Reims
Conditions Ventilator Associated Pneumonia
Enrollment 265 participants
Start Date 2025-03-06
Primary Completion 2026-09-06 (estimated)
Study Completion 2026-10-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-17